BioSyent Inc. (RX.V)
| Previous Close | 6.99 |
| Open | 6.99 |
| Bid | 6.90 x 0 |
| Ask | 7.00 x 0 |
| Day's Range | 6.99 - 7.00 |
| 52 Week Range | 6.59 - 9.59 |
| Volume | 24,575 |
| Avg. Volume | 3,609 |
| Market Cap | 88.817M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | 24.10 |
| EPS (TTM) | 0.29 |
| Earnings Date | Mar. 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Simply Wall St.
Is There An Opportunity With BioSyent Inc.'s (CVE:RX) 42% Undervaluation?
Today we will run through one way of estimating the intrinsic value of BioSyent Inc. ( CVE:RX ) by taking the forecast...
- GlobeNewswire
BioSyent Releases Q2 and H1 2021 Financial Results
MISSISSAUGA, Ontario, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include: Second quarter (Q2) 2021 Net Revenues of $7,289,254 increased by 53% versus Q2 2020First half (H1) 2021 Net Revenues of $14,709,143 increased by 36% versus H1 2020Record quarterly Canadian Pharmaceutical Net Revenues in Q2 2021 of $6,670,322 increased by 51% versus Q2 2020H1 2021 Canadian
- GlobeNewswire
BioSyent Schedules Q2 and H1 2021 Earnings Release for August 25, 2021
MISSISSAUGA, Ontario, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2021 on Wednesday, August 25, 2021 at 8:00am ET. A presentation on the Company’s second quarter and first half 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under
